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Abstract
Creating new molecules that simultaneously enhance tumor cell killing and permit diagnostic tracking is vital to overcoming
the limitations rendering current therapeutic regimens for terminal cancers ineffective. Accordingly, we investigated the
efficacy of an innovative new multi-functional targeted anti-cancer molecule, SM7L, using models of the lethal brain tumor
Glioblastoma multiforme (GBM). Designed using predictive computer modeling, SM7L incorporates the therapeutic activity
of the promising anti-tumor cytokine MDA-7/IL-24, an enhanced secretory domain, and diagnostic domain for non-invasive
tracking. In vitro assays revealed the diagnostic domain of SM7L produced robust photon emission, while the therapeutic
domain showed marked anti-tumor efficacy and significant modulation of p38MAPK and ERK pathways. In vivo, the unique
multi-functional nature of SM7L allowed simultaneous real-time monitoring of both SM7L delivery and anti-tumor efficacy.
Utilizing engineered stem cells as novel delivery vehicles for SM7L therapy (SC-SM7L), we demonstrate that SC-SM7L
significantly improved pharmacokinetics and attenuated progression of established peripheral and intracranial human GBM
xenografts. Furthermore, SC-SM7L anti-tumor efficacy was augmented in vitro and in vivo by concurrent activation of
caspase-mediated apoptosis induced by adjuvant SC-mediated S-TRAIL delivery. Collectively, these studies define a
promising new approach to treating highly aggressive cancers, including GBM, using the optimized therapeutic molecule
SM7L.
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Introduction
Successful management of many terminal cancer types has not
been achieved primarily because many conventional anti-cancer
therapies lack tumor specificity and exhibit poor or inadequate
pharmacokinetics that result in high toxicity to normal tissue,
limited bioavailability, and subsequently ineffective tumor cell
killing. Recently, the development of multifunctional therapeutics
offers unprecedented potential to overcome the limitations of
current anti-cancer therapies [1–5]. These powerful anti-cancer
therapies combine targeting specificity, optimized pharmacokinet-
ics, and diagnostic imaging capacity into a single agent. When
used in combination with effective delivery systems, these
multifunctional molecules have the potential to specifically target
tumors with high levels of localized therapies that can be
monitored in real-time by non-invasive imaging. Although widely
applicable, multifunctional molecules are especially well suited for
treatment of tumors in the brain where additional obstacles such as
the blood-brain-barrier make treating aggressive malignancies
particularly challenging [2]. Currently, no effective treatment has
been identified for the most common primary brain tumor,
Glioblastoma multiforme (GBM), and median survival rates
remain at approximately 1 year [6]. Therefore, new multifunc-
tional molecules offer a huge potential for successfully managing
terminal cancer types that include GBM.
To date, the majority of multifunctional agents are synthetic
nanoscale devices or nanoparticles chemically engineered with
tumor targeting and/or imaging components [2,3]. Novel
multifunctional DNA-encoded protein-based molecules offer
unique advantages over these devices, particularly for monitoring
secreted therapeutics delivered through unique cell-based appli-
cations. Despite their promise and wide applicability, few
multifunctional DNA-based molecules exist. Furthermore, the
fusion of multiple domains to create multifunctional DNA-based
molecules decreases the activity of the domains resulting in
PLoS ONE | www.plosone.org 1 July 2012 | Volume 7 | Issue 7 | e40234reduced diagnostic and/or therapeutic activity compared to the
parental molecules [1,7]. Consequently, creating molecules that
retain or enhance the functionality of the multiple domains
remains a significant challenge. Melanoma differentiation associ-
ated gene-7/interleukin-24 (MDA-7/IL-24) is a naturally occur-
ring anti-cancer cytokine that induces a strong tumor suppressive
effect in various cancer cell types while sparing normal cells [8,9].
Located on chromosome 1q32 [9], the anti-tumor effects of MDA-
7/IL-24 have been validated on cancer cell lines that include
melanoma [10], breast cancer [8,9,11,12], prostate cancer
[8,9,11,12], hepatocellular carcinoma [13], GBM [14–16] and
others [8,9,11,12,17]. In preclinical studies, MDA-7/IL-24
therapy has been shown to slow tumor progression both in vitro
and in vivo [15,16]. The effects of extracellular MDA-7/IL-24 are
mediated by binding to IL-20Ra/b receptors on tumors cells,
inducing modulation of the ERK, JNK, MAPK pathways to
induce anti-tumor effects [15]. Based on the potent anti-tumor
activity and receptor-targeted specificity of MDA-7/IL-24, we
reasoned that a novel and highly effective multifunctional anti-
cancer molecule could be created by re-engineering of wild-type
MDA-7/IL-24. However no studies to date have engineered
variants of MDA-7/IL-24 that alter it’s extracellular secretion,
functionality, or introduce diagnostic properties to the parental
molecule. We further speculated that both the pharmacokinetics
and anti-cancer efficacy of the novel multifunctional MDA-7/IL-
24 variant would be improved by delivery via engineered stem
cells. Our laboratory and others have shown that engineered stem
cells display inherent tumor-tracking properties that allow local
on-site secretion of therapies that increases delivery time and
decrease non-specific tissue binding [1,18–21].
In the current study, we engineered and validated a new
multifunctional molecule SM7L, and tested the anti-tumor efficacy
of stem cell-delivered SM7L therapy using models of the deadly
brain cancer GBM both in vitro and in vivo. SM7L was designed to
incorporate: 1) the anti-tumor domain of MDA-7/IL-24 to
introduce cancer cell-specificity and robust therapeutic activity,
2) light-emitting luciferase domain to impart diagnostic imaging
capacity, and 3) altered secretion sequence to optimize extracel-
lular delivery. Our results demonstrate the multifunctional
properties of SM7L and the efficacy of stem cell-mediated
SM7L therapy against highly aggressive brain tumor GBM. These
results define a promising new approach to treating highly
aggressive cancers using the multifunctional anti-cancer molecule
SM7L.
Results
Design and Validation of SM7L
Predictive molecular modeling was used to interrogate the
structure of wild type-MDA-7/IL-24, and provide a rational basis
for designing a potentially optimized molecule. The ‘‘bystander’’
antitumor effects of MDA-7/IL-24 protein are mediated by
binding to the IL-20R1/IL-20R2 and IL-22R1/IL-20R2 (IL-
20Ra/b) receptors (Fig. 1A) on the surface of cells [22–26]. Wild-
type-MDA-7/IL-24 monomers (Fig. 1B) aggregate to form dimers
(Fig. 1C), which then bind and activate defined molecular
pathways downstream of IL-20Ra/b receptors (Fig. 1D) to inhibit
tumor cell proliferation and survival. We hypothesized that an
ideal MDA-7/IL-24-based molecule for cell delivery would
contain: 1) maximal extracellular secretion for optimal delivery
of this therapeutic; 2) diagnostic properties for rapid non-invasive
tracking; and 3) a c-terminal fusion which would increase stability
of the molecule and improve functionality (Fig. 1E). Based on these
predictions, we designed SM7L (Fig. 1F) that contained a modified
secretion sequence derived from Flt-3 ligand and C-terminal
fusion of Gaussia luciferase to increase both stability and introduce
diagnostic properties. Molecular modeling suggested that this
molecule would retain the ability to efficiently dimerize (Fig. 1G)
and interact with cell-surface IL-20Ra/b receptors (Fig. 1H).
Furthermore, the modeling suggested the C-terminal fusion could
increase stability of the molecule in the binding pocket leading to
enhanced receptor activation and greater anti-tumor effects.
Characterizing Stem Cell-Delivered SM7L In Vitro
To allow easy and efficient transduction of cells with SM7L, we
next engineered lentiviral vectors encoding wild-type MDA-7/IL-
24 (M7) and the optimized SM7L (Fig. 2A). To assess the anti-
tumor activity of LV-SM7L, we transduced U87MG (high IL-
20Ra/b, Fig. S1) or H4 (low IL-20Ra/b) human GBM cells with
LV-SM7L, LV-M7 or control. As shown in figure 2B, cell viability
assays performed 5 days after transduction revealed LV-SM7L
significantly reduced cell viability in both cell lines, and to
comparable or greater levels than wild-type LV-M7. Due to the
robust response of U87 to SM7L treatment, this cell line was used
for all further experiments assessing therapeutic efficacy in this
study. Revealing the diagnostic properties of SM7L, biolumines-
cence imaging (BLI) of media from cells transduced with LV-
SM7L showed robust light emission that was absent in media from
control wild-type LV-M7 transduced cells (Fig. 2C), and showed
significantly higher extracellular photon emission than cells
expressing a MDA-7/IL-24-Gaussia luciferase fusion lacking the
Flt-3 signal sequence suggesting increased extracellular secretion
due to the modified secretion sequence in SM7L (Fig. 2C).
Next, we assessed the potential of utilizing the optimized SM7L
to create a novel multifunctional cell-based therapeutic for
simultaneous non-invasive tracking and tumor killing. Primary
mouse neural stem cells (mNSC) were engineered with LV
encoding SM7L (mNSC-SM7L), wild-type MDA-7/IL-24
(mNSC-M7), or control (mNSC-GFP), and transduction was
confirmed by fluorescence imaging (Fig. 2D). In vitro BLI showed a
direct correlation between mNSC-SM7L cell number and photon
emission (Fig. 2E), while longitudinal BLI revealed a stable
secretion of SM7L by stem cells through 10 days of culture
(Fig. 2F). To determine the anti-GBM effects of stem cell-delivered
SM7L and underlying molecular pathways, we performed co-
culture analysis of mNSC-M7, mNSC-SM7L, or mNSC-GFP with
U87 cells that were engineered to express the fusion of mCherry
and Firefly luciferase (FLuc). Quantitative FLuc imaging on day 3
and day 5 of co-culture revealed mNSC-SM7L significantly
inhibited U87 proliferation (Fig. 2G), and these results were
verified by similar findings in U251 and primary patient-derived
GBM8 tumor lines (Fig. S2). Western blot analysis showed robust
activation of p38MAPK and marked down regulation of ERK
signaling by mNSC-SM7L treatment in U87 (Fig. 2H). Taken
together these results demonstrate that the optimized variant,
SM7L, expands the functionality of wild-type MDA-7/IL-24 by
incorporating diagnostic tracking properties, promoting greater
extracellular secretion, and increasing anti-glioma activity.
Stem Cell-based Delivery Improves the Pharmacokinetics
of SM7L Delivery and Attenuates GBM Progression In
Vivo
We next determined which events in stem cell-mediated
delivery to tumors could be tracked by a combination of
multimodality imaging and diagnostic markers utilizing the
additional diagnostic properties of SM7L. To this end, GFP-
labeled stem cells secreting SM7L were implanted adjacent to
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window chambers (Fig. 3A). High-resolution intravital microscopy
performed on day 1 revealed the distribution of green SM7L-
secreting stem cells adjacent to red U87 gliomas, and these distinct
populations could be followed through day 5 (Fig. 3A). Monitoring
of SM7L levels by BLI revealed robust secretion at day 1 that had
declined slightly by day 5 (Fig. 3A–B, GLuc), while FLuc imaging
showed GBM volumes could be simultaneously monitored to
permit assessment of therapeutic efficacy (Fig. 3A–B, FLuc).
Together, these results show the combination of longitudinal
molecular imaging and diagnostic properties of SM7L permits
non-invasive simultaneous monitoring of SM7L levels, tumor
volumes, stem cell volumes, and cell distribution.
We utilized a molecular imaging approach to next investigate
the in vivo pharmacokinetics and therapeutic efficacy of SM7L
delivered by engineered stem cells. In the clinic setting, therapeutic
stem cells are typically injected directly into tumors. When mNSC-
SM7L were implanted around established U87-FLuc tumors to
mimic clinical cell engrafts typical of stem cell-based treatments,
bioluminescence imaging revealed a concentrated and stable
SM7L signal that co-localized with the established tumor and
showed no change in levels through 24 h (Fig. 3C). Ex vivo tissue
analysis showed SM7L was present in the excised tumor, but
absent from other organs (Fig. 3D). Importantly, the constant and
localized delivery of SM7L by stem cells lead to a marked
reduction in tumor volumes as early as day 2, assessed by Fluc
imaging (Fig. 3E). We next compared the pharmacokinetics of
stem cell-mediated SM7L delivery to purified SM7L delivered by
intravenous (IV) infusion to mimic the systemic or IV delivery
typically utilized for most clinical chemotherapies and therapeutic
proteins. Serial BLI showed the IV bolus of concentrated media
containing SM7L lead to widely-distributed levels shortly after
injection that were rapidly cleared by 24 h (Fig. 3F). Ex vivo tissue
analysis showed SM7L present in the blood, lung, kidney, liver, as
well as the tumor (Fig. 3G). FLuc imaging of tumor volumes
showed that intravenous SM7L had no significant effect on tumor
volumes (Fig. 3H). These results document that mNSC-SM7L
improves delivery and efficacy of MDA-7/IL-24 therapy, and the
diagnostic properties of SM7L provide previously unavailable
insights into real-time pharmacokinetics of this cytokine.
We next tested the efficacy of mNSC-SM7L in an intracranial
mouse model of GBM. U87-FLuc GBM cells were implanted with
mNSC-GFP-RLuc or mNSC-SM7L in the frontal lobe of mice.
Dual Fluc/Gluc and Fluc/Rluc imaging was used to track tumor
volumes/SM7L expression and tumor volumes/stem cell fate
respectively. As shown in figure 4A, longitudinal tracking of tumor
volumes by Fluc imaging revealed significant inhibition of GBM
growth by mNSC-SM7L compared to control-treated GBMs by
day 14, and this reduction in tumor progression persisted through
35 days. RLuc and Gluc imaging performed on day 29 confirmed
the presence of both stem cells and SM7L 4 weeks post-treatment
(Fig. 4A). Post-mortem immunohistochemical staining confirmed
the difference in tumor volumes and revealed a significant
reduction in Ki-67-positive GBM cells (Fig. 4B). Together, these
results provide strong evidence of the ability of mNSC-SM7L to
effectively inhibit growth of GBM in vivo.
SM7L and Concomitant Cytotoxic Treatment Enhance
GBM Cell Killing In Vitro and In Vivo
Despite the ability of mNSC-SM7L to inhibit GBM progres-
sion, residual GBM volumes were still detected at the termination
of mNSC-SM7L treatment. To strengthen SM7L-based therapy
we next investigated the efficacy of augmenting the cytostatic
effects of SM7L with agents that induce caspase-mediated cell
death that included radiation or a secreted variant of the potent
pro-apoptotic therapeutic protein TNF-a-related apoptosis-induc-
ing ligand (S-TRAIL). To investigate GBM therapy via activation
of multiple anti-tumor pathways, U87 (SM7L-sensitive, TRAIL
sensitive) and U251 (SM7L-sensitive; TRAIL semi-resistant [27])
Figure 1. Predictive computer modeling of wild-type MDA-7/IL-24 and optimized SM7L. Predictive space-filling models of IL-20a/b
receptor (A), MDA-7/IL-24 monomer (B), MDA-7/IL-24 dimer (C), and dimerized MDA-7/IL-24 binding to IL-20a/b receptor (D). (E) Representative
models of wild-type MDA-7/IL-24 and the modifications to optimize the molecule. These include modification of the secretion sequence (in red) and
C-terminal diagnostic fusion (yellow). (F-H) Space-filling models demonstrating the predicted structure of the modified MDA-7/IL-24 fusion protein
SM7L. (F) Representative computer model of SM7L monomer containing MDA-7/IL-24 (green) and C-terminal luciferase fusion (pink). (G) Computer
model showing a SM7L dimer. (H) Space filling model of SM7L dimmer interacting with IL-20a/b receptor.
doi:10.1371/journal.pone.0040234.g001
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TRAIL (200 ng); 4) radiation and SM7L; or 5) SM7L and S-
TRAIL (200 ng). As shown in the summary data (Fig. 5A), the
combination of SM7L and S-TRAIL lead to the greatest reduction
in viability of both GBM cell lines (U251–82%; U87–71%;
Fig. 5A). Additionally, while mNSC-SM7L co-cultured with U87
or U251 significantly slowed tumor cell proliferation, the addition
of mNSC secreting S-TRAIL (mNSC-S-TRAIL) converted the
cytostatic effects into a rapid reduction in GBM viability (Fig. 5B).
Providing insight into the molecular mechanism, SM7L/S-TRAIL
co-treatment lead to robust caspase 3/7 activation (Fig. 5C) and
cleavage of caspase-8 and PARP (Fig. 5D), effects that were not
observed by SM7L treatment alone (Fig. 5C–D). Interestingly, the
addition of S-TRAIL to SM7L-treated GBM increased
p38MAPK activation and ERK suppression to a greater extent
than SM7L alone (Fig. 5E). Taken together, these results reveal
that the combination of SM7L and S-TRAIL simultaneously
target both cell proliferation and apoptosis pathways to increase
GBM cell killing (Fig. 6).
To assess the in vivo efficacy of combined SM7L and S-TRAIL
therapy delivered by stem cells, we engineered double secreting
mNSC (mNSC-SM7L/S-TRAIL). U87-FLuc human GBM cells
were implanted intracranially in mice with control mNSC-GFP,
mNSC-SM7L, mNSC-S-TRAIL, or the double secreting mNSC-
SM7L/S-TRAIL. Serial Fluc imaging revealed mNSC-SM7L/S-
TRAIL induced a significant reduction in tumor volume that
persisted through 4 weeks of treatment (Fig. 5F). Although mNSC-
SM7L and mNSC-S-TRAIL also reduced GBM volumes, neither
mono-therapy was as effective as the mNSC-SM7L/S-TRAIL
combination treatment (Fig. 5F). These results were confirmed by
post-mortem IHC that showed the significant reduction in tumor
volumes by mNSC-SM7L/S-TRAIL (Fig. 5G), as well as an
upregulation in cleaved caspase-3 as revealed by immunostaining
(Fig. 5G).
Discussion
Multifunctional molecules offer significant potential to improve
treatment response and outcomes of patients suffering from cancer
[1–3]. However, few DNA-based molecules exist that incorporate
both highly functional therapeutic domains and diagnostic
imaging domains. In this study we report the design and validation
of SM7L, a unique multifunctional molecule with potent anti-
tumor effects derived from enhancement of the therapeutic
cytokine MDA-7/IL-24 and diagnostic properties due to incor-
poration of a photon-emitting luciferase. Used in combination
with real-time non-invasive imaging and stem cell-based delivery,
Figure 2. In vitro characterization of stem cell-delivered SM7L. (A) Lentiviral transfer vectors were engineered to encode: (1) wild-type MDA-7/
IL-24 (M7) and (2) SM7L. The modified secretion sequence is shown in red and the luciferase fusion is shown in yellow. All MDA-7/IL-24 variants were
cloned upstream of IRES-GFP. (B) Summary data demonstrating the effects of SM7L on U87 or H4 human GBM cells. Tumor cells were transduced with
lentiviral vectors encoding SM7L, M7, or GFP and the therapeutic activity of each variant was determined 5 days post-transduction. (C) Representative
BLI images and summary data showing the extracellular levels of SM7L, wild-type M7, or a wild-type M7 diagnostic fusion lacking a modified
secretion sequence (M7L). 293 T cells were transduced with equal MOI of LV-SM7L, LV-M7, or LV-M7L and seeded at increasing cell numbers in 96-
well plates. Forty-eight h later, equal volumes of media were transferred to new wells and BLI imaging was performed on media. (D) Representative
images of stem cell cells transduced with LV encoding GFP (control), M7, or SM7L. (E) Summary graph demonstrating the linear correlation between
mNSC-SM7L cell number and photon emission. mNSC-SM7L were seeded at increasing cell numbers (0.1–2610
4 cells), combined with coelenterazine
15 mg, and photon emission was determined in a luminometer. (F) Summary data demonstrating the stability of SM7L expression by mNSC. mNSC
were transduced with LV-SM7L, and 1, 3, 5, and 10 days post-transduction, cells (1610
5 cells) were collected, combined with coelenterazine (15 ml),
and SM7L photon emission was determined using a luminometer. Data is expressed relative to cell number determined by luciferase-based assay. (G)
Representative images and summary graphs of cell viability assays performed on U87 human GBM co-cultured with mNSC-GFP, mNSC-M7, or mNSC-
SM7L. U87-Fluc-mcherry GBM cells were seeded in 96 well plates. 24 h later, control or mNSC secreting wild-type or SM7L were overlayed on the cells.
Three and five days later, Fluc imaging was performed to determine the effects of stem cell-delivered M7 or SM7L on GBM cell growth. (H) Western
blot performed on lysates from U87 GBM cells treated with conditioned media from control, mNSC-M7 or mNSC-SM7L. Cell lysates from treated cells
were immunoblotted using antibodies against phosphorylated and non-phosphorylated p38 MAPK or ERK. In all panels, *p,0.05 vs. control, and
experiments were performed in triplicate with mean and SD reported.
doi:10.1371/journal.pone.0040234.g002
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insights into the pharmacokinetics of SM7L therapy while the
therapeutic domain markedly attenuated progression of highly
malignant or highly invasive GBM as mono- or combination
therapy. Together, these results demonstrate the efficacy and
versatility of the multifunctional molecule SM7L for cancer
therapy.
MDA-7/IL-24 is a distinctive cytokine that uniquely displays
potent anti-cancer activity toward a broad-spectrum of human
cancers, without provoking toxicity in normal cells or tissues
[8,9,11,12,17,28]. The molecule is composed of a central
consensus sequence that has close homology to members of the
IL-10 cytokine gene family, and a N-terminal secretion sequence
that drives extracellular release [8,9,11,12,23,24,28]. The effects of
extracellularly delivered MDA-7/IL-24 are mediated through
interactions with IL-20Ra/b receptors on the cell surface, and the
natural secretion of MDA-7/IL-24 leads to ‘‘bystander’’ effects via
binding to surface receptors on adjacent and distant tumor cells
resulting in stabilization, production and secretion of MDA-7/IL-
24 by autocrine/paracrine processes [25,26]. The primary goal of
this study was to enhance the therapeutic potential of MDA-7/IL-
24 by designing a new molecule that exploits the anti-tumor
domain of wild-type MDA-7/IL-24. We theorized that this could
be achieved by introducing diagnostic properties to serially
monitor therapeutic levels and through enhanced secretion to
increase extracellular levels and subsequent activation of IL-
20Ra/b receptors. The resulting molecule, SM7L, is distinctive
and contains the therapeutic domain of MDA-7/IL-24 flanked by
the Flt-3 ligand signal sequence on the N-terminus and the
diagnostic molecule Gaussia luciferase on the C-terminus.
Predictive computer modeling suggested that the C-terminal
fusion of MDA-7/IL-24 would allow MDA-7/IL-24 to retain
Figure 3. mNSC-SM7L improves the pharmacokinetics of delivery and enhances anti-GBM efficacy in vivo. (A–B) Representative images
and summary graph showing in vivo imaging of multiple events in stem cell delivery of SM7L. mNSC-SM7L were implanted around established
U87Fluc-mCherry tumors in subcutaneous skin flap window chambers. Intravital microscopy was used to visualize stem cell (green) and tumor (red)
volumes at cellular resolution 1 and 5 days post-implantation (A). Simultaneously, Fluc and GLuc imaging was used to monitor changes in tumor
volume (Fluc) and SM7L (GLuc) secretion respectively (A). Fluorescent intensities and BLI photon emission was then quantified to reveal stem cell
volume, tumor volumes, and SM7L levels (B). In the panels, tumors=Fluc, red; stem cells=green; SM7L secretion=GLuc. (C–H) Summary of
experiments to visualize differences in pharmacokinetics of stem cell-delivered and intravenous (IV) injection of SM7L. (C) Representative Fluc (tumor)
and GLuc (SM7L) images and summary data showing SM7L levels delivered by engineered stem cells implanted around established U87-Fluc tumors
at 0 and 24 h post-implantation (n=3). (D) Ex vivo analysis of stem cell-delivered SM7L biodistribution performed by GLuc bioluminescent imaging of
multiple excised tissues. (E) Summary graph of Fluc imaging performed on days 0, 2, 7, and 10 showing mNSC-SM7L inhibition of tumor progression
compared to tumors treated with control stem cells. (F–H) In vivo imaging of conditioned medium containing SM7L injected by IV infusion. Following
implantation of FLuc-positive tumors (F), a bolus of media containing SM7L was injected IV followed immediately by coelenterazine. Images were
captured at 5–50 mins and 24 h post-injection (F, n=3). Representative Fluc (tumor) and GLuc (SM7L) images and summary graphs revealing levels
(F) and distribution in excised tissue (G) are shown. (H) Fluc imaging was performed on days 1, 3, 7 and 10 post-injection to determine tumor
volumes.
doi:10.1371/journal.pone.0040234.g003
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potentially increase molecular stability. Furthermore, replacement
of the endogenous MDA-7/IL-24 secretion sequence with the
signal sequence from the Flt-3 ligand was anticipated to achieve
the desired enhancement in extracellular secretion. When the
hypothetical molecule was engineered and tested, our results
corroborated the predictive modeling. The optimized SM7L
retained anti-tumor properties, robust luciferase activity, and the
new signal sequence lead to enhanced secretion. The precise
mechanisms by which the fusions in SM7L contribute to all of
these increased activities are unclear, however previous data has
suggested GST fusion to MDA-7/IL-24 increased the intracellular
activity of the molecule, potentially via enhanced uptake and
protein stabilization [29]. This finding suggests that the fusion of
luciferase to MDA-7/IL-24 may function in a similar way to
increase protein stabilization, but further research is required to
prove this hypothesis. The enhanced anti-tumor toxicity of SM7L
involves enhanced modulation of the ERK and MAPK signaling
pathways (Fig. 2), key mediators of MDA-7/IL-24 tumor toxicity.
In total, these results demonstrate the advantages of SM7L and the
potential of utilizing predictive modeling to design optimized
molecules that improve the anti-tumor efficacy of therapy
treatments.
Our results show that a single administration of mNSC-SM7L
significantly delayed peripheral and intracranial GBM progres-
sion. Previously, most MDA-7/IL-24 therapies were contingent on
ex vivo transduction or multiple infusions of a replication
incompetent Ad5. While this approach was shown to slow
intracranial GBM progression [16], ex vivo infection of cells lacks
clinical translatability and multiple Ad5 injections increase the
complexity of the therapy and leads to activation of the host
immune system thereby promoting neutralization of the thera-
peutic virus. Using the diagnostic properties of SM7L, a single
mNSC-SM7L engraftment lead to highly localized and stable
therapeutic delivery for days to weeks in vivo. In these experiments,
we chose the method of delivery most commonly used in the
clinics for stem cell or purified protein/chemotherapeutic delivery.
The vast majority of pre-clinical studies have evaluated efficacy
using direct intratumoral injection of therapeutic stem cells in
GBM models [18,30–32]. We have also shown that IV delivery of
stem cells leads to significantly lower percentage of cells at the site
of GBM compared to intratumoral injection [33,34], and studies
have shown the majority of stem cells accumulate in the lung
following IV injection [33,34]. Further demonstrating the clinical
relevancy of intratumoral injection, the first clinical trial of stem
cell-delivered targeted therapy for GBM was recently initiated at
the City of Hope National Medical Center and uses local
intratumoral stem cell injection. For these cumulative reasons,
we chose to focus only on stem cells injected into the tumor and
not IV. In contrast, many chemotherapies and purified protein
therapies are administered systemically, either orally or IV.
Therefore, we chose to investigate IV delivery of purified SM7L
for comparison. Interestingly, our results showed a slight decrease
in stem cell volumes and SM7L levels five days post-implantation.
Although the precise underlying cause is unclear, we have
previously observed a similar decrease of approximately 20% in
stem cell volumes in the days following implantation [21]. We
speculate that stem cell death may be due to small sub-populations
of cells being damaged during implantation that then die shortly
after injection, or some cells not being sustained by the brain
microenvironment following implantation. Despite the cause of
the cell death, we have never previously been able to detect the
effect the decrease in stem cell volume has on therapeutic delivery.
Our results show the decrease in SM7L parallels the decrease in
stem cell volume, and the diagnostic properties of SM7L will allow
optimization of dosing to maximize tumor cell killing in future
studies. Accordingly, eliminating the need for multiple injections,
coupled with the enhanced anti-tumor properties and diagnostic
capacity of SM7L suggests that stem cell-delivered SM7L therapy
will be superior to current MDA-7/IL-24 therapy for GBM when
this cytokine is delivered using a replication incompetent Ad5.
Despite the promise of MDA-7/IL-24 and SM7L therapy, the
results of this study and multiple other studies suggest that these
mono-therapies primarily slow tumor cell growth and the
remaining residual tumor has the potential for rapid tumor
recurrence upon termination of the therapy. To improve
therapeutic efficacy, MDA-7/IL-24 has been combined with
cytotoxic and immune therapies for treatment of GBM
[8,9,11,12,35,36]. However, a limitation of the prior studies was
the need for ex vivo manipulation to observe significant effects in
Figure 4. mNSC-SM7L prolongs SM7L delivery and attenuates GBM progression. (A) Representative FLuc bioluminescent images and
summary data of mice implanted intracranially with mNSC transduced with LV-GFP-RLuc (n=6) or SM7L (n=6) and U87-Fluc GBM cells. FLuc
bioluminescence imaging was performed from day 1 to day 35 to monitor tumor progression. On day 29, Rluc imaging was performed to determine
stem cell volume and GLuc imaging was performed to confirm SM7L secretion. (B) Immunohistochemistry with antibodies against Ki67 and summary
data performed on sections from brains treated with control and mNSC-SM7L 29 days post-implantation. Representative images show brain sections
containing mNSC (green) or Ki67 staining (red). In all panels, *p,0.05 vs. control, and mean and SD are reported.
doi:10.1371/journal.pone.0040234.g004
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tic outcomes, the effects were insufficient and significant tumor
burden was typically observed at the termination of therapy. In
contrast, we observed the combination of mNSC-SM7L/TRAIL
nearly eliminated tumor burden within 5 days of treatment,
induced greater GBM killing than the combination of MDA-7/IL-
24 and radiation, and was observed without pre-treatment of cells
prior to implantation. The effectiveness of MDA-7/IL-24/TRAIL
therapy has been reported in models of colorectal cancer [37],
where co-administration of oncolytic adenovirus encoding MDA-
7/IL-24 and TRAIL eradicated tumors in mice. In addition to
dual activation of both the apoptotic cascade and the complex
MDA-7/IL-24 signaling pathways, studies have suggested that
MDA-7/IL-24 treatment further enhance the efficacy of concom-
itant TRAIL therapy by upregulating TRAIL death receptors or
increasing the release of TRAIL from tumor cells [38]. This
suggests the potential for synergistic cell killing by MDA-7/IL-24
and TRAIL therapy which was not observed in our study. While
the full mechanism mediating MDA-7/IL-24 and TRAIL
combination therapy remains to be elucidated, clearly the
combination of MDA-7/IL-24 and TRAIL simultaneously target
both cell proliferation and apoptosis pathways to increase GBM
cell killing (Fig. 6) and may be a highly efficacious approach to
treating GBM and potentially other malignant neoplasms.
Figure 5. Combined targeting of cytostatic and cytotoxic pathways with stem cell delivered SM7L and S-TRAIL improves anti-GBM
efficacy in vitro and in vivo. (A) Summary graph of the viability of U251 and U87 GBM cells pre-treated with radiation (4 Gy) and SM7L or SM7L
followed by concentrated S-TRAIL. U251 and U87 GBM cells were incubated with SM7L or irradiated with 4 Gy., and treated or untreated cells were
incubated with S-TRAIL (200 ng) overnight, and cell viability was determined by luciferase-based assay. (B) Summary data and representative images
demonstrating the effects on cell viability of U251 and U87 GBM cells co-cultured with stem cell secreting SM7L or SM7L/S-TRAIL. Control or SM7L
mNSC were overlayed on Fluc-positive GBM cells. Four days later, mNSC-STRAIL were seeded onto a subset of mNSC-SM7L and cell viability was
determined by luciferase assay 24 h later. (C) Caspase 3/7 activation assay performed on U87 and U251 cells treated with conditioned media
containing SM7L, S-TRAIL, SM7L/S-TRAIL, or control. (D-E) Western blot and summary graph performed on U87 and U251 cells treated with
conditioned media containing SM7L and/or S-TRAIL. Cell lysates were collected and immunoblotted with antibodies against cleaved PARP, total and
cleaved caspase-8 (D) as well as total and phosphorylated p38MAPK or ERK (E). (F) Representative images and summary data demonstrating the
effects of stem cell-delivered SM7L or S-TRAIL monotherapy or SM7L/S-TRAIL concomitant therapy delivered by dual secreting stem cells on the
progression intracranial U87-Fluc human GBMs. mNSC-GFP (control, n=10), mNSC-SM7L (n=10), mNSC-S-TRAIL (n=8), or double secreting mNSC-
SM7L/S-TRAIL (n=8) were implanted together with U87-Fluc GBM cells in the frontal lobe of mice. Serial Fluc bioluminescence imaging was
performed on days 0 and 29 to monitor therapeutic efficacy. (G) Representative photomicrographs and summary graph of coronal brain sections
stained with H&E and corresponding fluorescence immunostaining showing mNSC distribution (GFP) or the levels caspase-3 (red, summary graph) in
mice treated with mNSC-GFP (control), mNSC-SM7L, mNSC-S-TRAIL, or double secreting mNSC-SM7L/S-TRAIL. In all panels, *p,0.05 vs. control;
1p,0.05 vs. SM7L, and experiments were performed in triplicate with mean and SD reported.
doi:10.1371/journal.pone.0040234.g005
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and enhance survival of patients with terminal cancers, new and
more effective therapies are mandated. Building on the promising
therapeutic cytokine MDA-7/IL-24, mNSC-SM7L provides
specific advantages over replication incompetent Ad5 delivery of
unmodified parental MDA-7/IL-24 that include superior anti-
tumor efficacy, improved targeted delivery, and the ability to
longitudinally track the therapeutic. When combined with
simultaneous cytotoxic therapy, mNSC-SM7L/TRAIL potently
eradicated malignant human GBM in vivo. In light of these
advantages, we anticipate clinical application of stem cell-
mediated delivery of SM7L holds promise to significantly benefit
patients suffering from GBM and potentially other cancers.
Materials and Methods
Generation of Lentiviral Vectors Encoding MDA-7/IL-24
Fusion Variants
The lentiviral transfer plasmid CS-CGW [39,40] was used as
the backbone for all LV constructs. To create LV-MDA-7/IL-24
(M7), the cDNA sequence encoding MDA-7/IL-24 was PCR
amplified using the vector porf-hil24 (Invivogen, San Diego CA) as
a template. The restriction sites were incorporated into the
primers, the resulting fragment was digested with Nhe1 and Xho1,
and ligated in-frame into Nhe1/Xho1 digested CSCGW plasmid.
To create LV-ssmda-7 (SM7), cDNA encoding the 60 bp signal
sequence of Flt-3 ligand was amplified with primers including Nhe1
and BamH1 restriction sites using previously described DNA as
template [41]. The cDNA encoding MDA-7/IL-24 without the
endogenous signal sequence was amplified with primers containing
BamH1 and Xho1 restriction sites. The two fragments were digested
and ligated into CSCGW plasmid digested Nhe1/Xho1.T o
engineer the luciferase fusion variants, the cDNA encoding Gaussia
luciferase (Gluc) was amplified using the pGluc-Basic vector (New
England Biolabs, Ipswich MA) as a template with primers
containing EcoV and Xho1 restriction sites. Both LV-SM7 and
LV-M7 vectors contained an EcoV site in the c-terminus of MDA-
7/IL-24. Both vectors were digested with EcoV and Xho1, and the
Gluc fragments were ligated in-frame. LV-Fluc-mCherry was
kindly provided by Dr. Andrew Kung (Dana-Farber Cancer
Institute, Boston MA). Lentiviral vectors were produced by
transient transfection of 293 T cells as previously described [27].
Cell Lines
Human glioblastoma cell lines U87-Fluc (a kind gift from Claire
Sauvageot, Brigham and Women’s Hospital, Boston, MA) [42].
H4, and U251, as well as 293 T cells were purchased from
American Type Culture Collection (ATCC, Manassas, VA) and
cultured as previously described [1,21,43,44]. Primary mouse
neural stem cells were purchased from Stem Cell Technologies
and cultured as previously described [1].
Tumor Models and In Vivo Bioluminescent Imaging
In this study, several tumor models were utilized. In all studies, a
4 ml injection volume was used for tumor cells and a 6 ml injection
volume was used for stem cells. All experimental protocols were
approved by The Subcommittee on Research Animal Care at
Massachusetts General Hospital, and care of the mice was in
accordance with the standards set forth by the National Institutes
of Health Guide for the Care and Use of Laboratory Animals, USDA
regulations, and the American Veterinary Medical Association: 1)
To determine the effects of stem cell-delivered SM7L on
intracranial GBMs, 2610
5 U87-Fluc human glioma cells and
1610
5 mNSC expressing SM7L or control (GFP-Rluc) were
implanted stereotactically into the right frontal lobe of SCID mice
(from bregma: –2 mm lateral, 22 mm ventral). On days 1,3, 6, 8,
14, 22, 29, and 35 post-injection mice received an intraperitoneal
injection of D-luciferin (2 mg; prepared in 150 ml of saline) and
tumor progression was monitored by FLuc imaging. On day 29
post-implantation, a subset of mice from control (mNSC-GFP-
Rluc) and mNSC-SM7L treatment groups were injected with
coelenterazine (100 mg) and Rluc or Gluc imaging was performed
to assess stem cell volumes or SM7L levels respectively. 2) To
determine the effects of stem cell-based SM7L/S-TRAIL combi-
nation therapy on intracranial GBMs, 2610
5 U87-Fluc human
glioma cells and 1610
5 mNSC expressing SM7L, S-TRAIL,
SM7L/S-TRAIL or control (GFP-Rluc) were implanted stereo-
tactically into the right frontal lobe of SCID mice (from bregma: –
2 mm lateral, 22 mm ventral). Tumor progression was then
monitored by FLuc imaging on days 1 and 29 as described above.
All the other methods utilized in this study are described in detail
in Methods S1 section.
Statistical Analysis
Data are expressed as mean6SD and were analyzed by either
Student’s T-test or ANOVA (after Bartlett’s test of homogeneity of
variance), followed by the Newman-Keuls correction for multiple
comparisons. Differences were considered significant at P,0.05.
Supporting Information
Figure S1 Levels of IL20a/b receptors in GBM cell lines.
(A) Relative expression of IL20a/b receptors on various GBM
Figure 6. Proposed signaling changes following combined
SM7L/S-TRAIL therapy. Schematic simplified overview of pathways
proposed to mediate the anti-tumor effects of MDA-7/IL-24 and TRAIL
combination therapy. MDA-7/IL-24 primarily induces cytostatic effects
through alterations in p38MAPK and ERK signaling. TRAIL induces
apoptosis via activation of the caspase cascade. Elevation in these
pathways were observed following combination treatment. Speculative
points of cross-talk are labeled in grey. MDA-7/IL-24 up-regulates the
levels of TRAIL in certain cell lines and down-regulates the TRAIL
inhibitor FLIP. TRAIL has been reported to downregulate ERK in GBM
cell lines leading to increased caspase activation.
doi:10.1371/journal.pone.0040234.g006
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triplicate with mean and SD reported.
(TIF)
Figure S2 In vitro characterization of stem cell-deliv-
ered SM7L on glioma line, U251. (A) Representative images
and summary graphs of cell viability assays performed on U251
established human GBM cells co-cultured with mNSC-GFP,
mNSC-M7, or mNSC-SM7L. U251-Fluc-mcherry GBM cells
were seeded in 96 well plates. 24 hrs later, control or mNSC
secreting wild-type or SM7L were overlayed on the cells. Three
and five days later, Fluc imaging was performed to determine the
effects of stem cell-delivered M7 or SM7L on GBM cell growth.
(B) Summary data demonstrating the viability of GBM8 primary
patient-derived cells co-culutred with mNSC-GFP or mNSC-
SM7L. Cell viability was determined by Fluc imaging 1, 3, and 5
days post-treatment. *p,0.05 vs. control. Experiments were
performed in triplicate with mean and SD reported.
(TIF)
Methods S1 This section includes details on LV transduction,
molecular modeling, caspase and viability assays, in vitro
bioluminescence imaging and fluorescence microscopy, western
blot analysis, quantitative RT-PCR, tumor models and in vitro and
in vivo imaging.
(DOC)
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